Biography:Charles Swanton
Charles Swanton | |
|---|---|
| Born | Robert Charles Swanton |
| Education | UCL Medical School |
| Alma mater | University of London (PhD) |
| Awards | Ellison–Cliffe Lecture |
| Scientific career | |
| Fields | Cancer[1] |
| Thesis | Viral cyclin disruption of mammalian cell cycle control mechanisms (1998) |
| Doctoral advisor | Nic Jones |
| Doctoral students | Nicholas Mcgranahan, Rebecca Burrell, Mariam Jamal Hanjani, Tom Webber, Tom Watkins, Rachel Rosenthal, Sally Dewhurst, Alvin Lee |
| Influences | Julian Downward |
| Website | www |
(Robert) Charles Swanton FRS FMedSci FRCP is senior group leader at the Francis Crick Institute,[2] Royal Society Napier Professor in Cancer and director of the Cancer Research UK (CRUK) Lung Cancer Centre of Excellence and thoracic medical oncologist at University College London and University College London Hospitals.[3]
Swanton completed his MD–PhD training in 1999[4] at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008.[3] Swanton combines his laboratory research with clinical duties as director of the CRUK University College London (UCL) Lung Cancer Centre, focussed on how tumours evolve over space and time.[3] He has helped to define the branched evolutionary histories of solid tumours, processes that drive cancer cell-to-cell variation in the form of new cancer mutations or chromosomal instabilities, and the impact of such cancer diversity on effective immune surveillance and clinical outcome.[1][3][5][6]
Swanton was awarded the Pontecorvo ICRF PhD thesis prize in 1997, Jeremy Jass Prize in pathology (2014), Stand up to Cancer Translational Cancer Research Prize in 2015, the Glaxo Smithkline Biochemical Society Prize in 2016, the San Salvatore prize for Cancer Research in 2016, CRUK Translational Research Prize (2017), the Ellison-Cliffe Medal by the Royal Society of Medicine in 2017 and the Massachusetts General Hospital Cancer Centre Kraft Prize (2018) and the Gordon Hamilton Fairley Medal and Lecture (2018).[3][7] He was elected a Fellow of the Royal College of Physicians in 2011, Fellow of the Academy of Medical Sciences in 2015, EMBO member in 2017 and a Fellow of the Royal Society in 2018.[3]
Swanton is a co-founder of Achilles Therapeutics with Sergio Quezada, Karl Peggs and Mark Lowdell. Achilles Therapeutic is a UCL/CRUK and Francis Crick Institute biotechnology company funded by Syncona that develops adoptive T cell therapies targeting clonal/truncal neo-antigens present in every tumour cell to limit drug resistance and tumour evolution.
References
- ↑ 1.0 1.1 {{Google Scholar id}} template missing ID and not present in Wikidata.
- ↑ "Charles Swanton - The Francis Crick Institute". https://www.crick.ac.uk/research/a-z-researchers/researchers-p-s/charles-swanton/.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Anon (2018). "Professor Charles Swanton FMedSci FRS". London: Royal Society. https://royalsociety.org/people/charles-swanton-13849/. One or more of the preceding sentences incorporates text from the royalsociety.org website where: “All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License.” --
- ↑ Swanton, Robert Charles (1998). Viral cyclin disruption of mammalian cell cycle control mechanisms. london.ac.uk (PhD thesis). University College London (University of London). OCLC 941060556. EThOS uk.bl.ethos.286205.
- ↑ Swanton, Charles; Mann, David J.; Fleckenstein, Bernhard; Neipel, Frank; Peters, Gordon; Jones, Nic (1997). "Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins". Nature 390 (6656): 184–187. doi:10.1038/36606. ISSN 0028-0836. PMID 9367157.
- ↑ Charles Swanton publications indexed by the Scopus bibliographic database. (Subscription content?)
- ↑ Azvolinsky, Anna (2018). "Cancer Evolutionist: A Profile of Charles Swanton". The Scientist. https://www.the-scientist.com/?articles.view/articleNo/52091/title/Cancer-Evolutionist--A-Profile-of-Charles-Swanton.
 |
